



In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant *Enterobacteriaceae* and Isolates Carrying Carbapenemase Genes

Mariana Castanheira,^a Andrew P. Davis,^a Rodrigo E. Mendes,^a Alisa W. Serio,^b Kevin M. Krause,^b Robert K. Flamm^a

^aJMI Laboratories, North Liberty, Iowa, USA

^bAchaogen, South San Francisco, California, USA

ABSTRACT Plazomicin and comparator agents were tested by using the CLSI reference broth microdilution method against 4,825 clinical isolates collected during 2014 and 2015 in 70 U.S. hospitals as part of the ALERT (Antimicrobial Longitudinal Evaluation and Resistance Trends) program. Plazomicin (MIC₅₀/MIC₉₀, 0.5/2 μg/ml) inhibited 99.2% of 4,362 *Enterobacteriaceae* at ≤4 μg/ml. Amikacin, gentamicin, and tobramycin inhibited 98.9%, 90.3%, and 90.3% of these isolates, respectively, by applying CLSI breakpoints. The activities of plazomicin were similar among *Enterobacteriaceae* species, with MIC₅₀ values ranging from 0.25 to 1 μg/ml, with the exception of *Proteus mirabilis* and indole-positive *Proteaeae* that displayed MIC₅₀ values of 2 μg/ml. For 97 carbapenem-resistant *Enterobacteriaceae* (CRE), which included 87 isolates carrying *bla*_{KPC}, plazomicin inhibited all but 1 isolate at ≤2 μg/ml (99.0% and 98.9%, respectively). Amikacin and gentamicin inhibited 64.9% and 56.7% of the CRE isolates at the respective CLSI breakpoints. Plazomicin inhibited 96.5 and 95.5% of the gentamicin-resistant isolates, 96.9 and 96.5% of the tobramycin-resistant isolates, and 64.3 and 90.0% of the amikacin-resistant isolates according to CLSI and EUCAST breakpoints, respectively. The activities of plazomicin against *Pseudomonas aeruginosa* (MIC₅₀/MIC₉₀, 4/16 μg/ml) and *Acinetobacter* species (MIC₅₀/MIC₉₀, 2/16 μg/ml) isolates were similar. Plazomicin was active against coagulase-negative staphylococci (MIC₅₀/MIC₉₀, 0.12/0.5 μg/ml) and *Staphylococcus aureus* (MIC₅₀/MIC₉₀, 0.5/0.5 μg/ml) but had limited activity against *Enterococcus* spp. (MIC₅₀/MIC₉₀, 16/64 μg/ml) and *Streptococcus pneumoniae* (MIC₅₀/MIC₉₀, 32/64 μg/ml). Plazomicin activity against the *Enterobacteriaceae* tested, including CRE and isolates carrying *bla*_{KPC} from U.S. hospitals, supports the development plan for plazomicin to treat serious infections caused by resistant *Enterobacteriaceae* in patients with limited treatment options.

KEYWORDS aminoglycosides, plazomicin, carbapenem-resistant *Enterobacteriaceae*

The worldwide emergence of multidrug-resistant (MDR) organisms, including carbapenem-resistant *Enterobacteriaceae* (CRE), *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*, highlights the need for new therapeutic options to treat infections (1). In the early 2000s, the Infectious Diseases Society of America recognized the urgent need for surveillance initiatives and new therapeutic options for the group of organisms known as ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *A. baumannii*, *P. aeruginosa*, and *Enterobacter* species), which includes Gram-negative organisms as well as troublesome Gram-positive species (2).

New therapeutic options for Gram-positive and -negative organisms were recently

Received 14 February 2018 Returned for modification 2 March 2018 Accepted 12 May 2018

Accepted manuscript posted online 4 June 2018

Citation Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. 2018. In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant *Enterobacteriaceae* and isolates carrying carbapenemase genes. Antimicrob Agents Chemother 62:e00313-18. <https://doi.org/10.1128/AAC.00313-18>.

Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to Mariana Castanheira, mariana-castanheira@jmilabs.com.

approved for clinical therapy in the United States and Europe (3); however, developing new agents with broad-spectrum activity is important given the significance of adequate empirical treatment for successful patient outcomes (4, 5).

Aminoglycosides are broad-spectrum agents that have been used for several decades to treat serious infections caused by nonfastidious Gram-negative bacteria, staphylococci, enterococci, and viridans group streptococci. Aminoglycosides are also used in combination with other agents displaying synergistic activity with this class, such as β -lactams, fluoroquinolones, polymyxins, and vancomycin (3). The most common mechanisms of resistance to aminoglycosides are aminoglycoside-modifying enzymes (AMEs) that are broadly disseminated among Gram-negative and Gram-positive species and carried by mobile genetic structures that also often harbor β -lactamases and other resistance genes (6, 7).

Plazomicin is a semisynthetic aminoglycoside derived from sisomicin and contains structural modifications that make this molecule stable in the presence of most AMEs (8, 9). Plazomicin has *in vitro* activity against nonfastidious Gram-negative pathogens and *Staphylococcus* spp., including methicillin-resistant *S. aureus* isolates (10, 11).

In this study, we evaluated the activities of plazomicin and comparator antimicrobial agents tested against 4,825 clinical isolates collected in U.S. hospitals during 2014 and 2015. *Enterobacteriaceae* isolates displaying elevated carbapenem MIC values were evaluated for carbapenemase genes, and a separate analysis focused on the activities of plazomicin and comparators against these subsets.

RESULTS

Activities of plazomicin and comparator agents. Plazomicin (MIC₅₀ and MIC₉₀, 0.5 and 2 μ g/ml, respectively) inhibited 99.2% of 4,362 *Enterobacteriaceae* isolates tested at ≤ 4 μ g/ml (Table 1). For common *Enterobacteriaceae* species, plazomicin inhibited 99.9% of the 1,506 *K. pneumoniae* isolates (MIC₅₀ and MIC₉₀, 0.25 and 0.5 μ g/ml, respectively), 99.9% of the 1,346 *Escherichia coli* isolates (MIC₅₀ and MIC₉₀, 0.5 and 1 μ g/ml, respectively), and 99.4% of the 359 *Klebsiella oxytoca* isolates (MIC₅₀ and MIC₉₀, 0.5 and 0.5 μ g/ml, respectively) at ≤ 4 μ g/ml (Table 1).

Plazomicin inhibited all 104 *Enterobacter cloacae* species complex isolates (here *E. cloacae*) (MIC₅₀ and MIC₉₀, 0.5 and 0.5 μ g/ml, respectively) at ≤ 2 μ g/ml and all 120 *Enterobacter aerogenes* (MIC₅₀ and MIC₉₀, 0.5 and 1 μ g/ml, respectively), 159 *Citrobacter freundii* species complex (MIC₅₀ and MIC₉₀, 0.5 and 1 μ g/ml, respectively), 145 *Citrobacter koseri* (MIC₅₀ and MIC₉₀, 0.25 and 0.5 μ g/ml, respectively), and 107 *Serratia marcescens* (MIC₅₀ and MIC₉₀, 1 and 2 μ g/ml, respectively) isolates at ≤ 4 μ g/ml (Table 1).

Overall, plazomicin inhibited 90.7%, 91.1%, 98.4%, and 99.1% of the *Morganella morganii*, *Providencia* species, *Proteus mirabilis*, and *Proteus vulgaris* group isolates at ≤ 4 μ g/ml, respectively (Table 1). Plazomicin MIC₅₀ values for *Morganella morganii*, *Proteus mirabilis*, and *Proteus vulgaris* (2, 2, and 2 μ g/ml, respectively) were identical to the MIC₅₀ values displayed by amikacin (2, 2, and 2 μ g/ml, respectively), while gentamicin (0.5, 1, and 0.5 μ g/ml, respectively) and tobramycin (0.5, 0.5, and 0.5 μ g/ml, respectively) (data not shown) had 2- to 4-fold-lower MIC₅₀ values. Plazomicin displayed MIC₅₀ values (range, 0.25 to 1 μ g/ml) lower than those observed for amikacin (2 to 1 μ g/ml) for all remaining *Enterobacteriaceae* species and were similar to those observed for gentamicin (0.5 μ g/ml for all species) and tobramycin (range, 0.25 to 2 μ g/ml). The MIC₅₀ values of all 4 aminoglycosides were very similar (range, 1 to 2 μ g/ml) for *Providencia* species isolates (data not shown).

Amikacin (MIC₅₀ and MIC₉₀, 1 and 4 μ g/ml, respectively), gentamicin (MIC₅₀ and MIC₉₀, 0.5 and 4 μ g/ml, respectively), and tobramycin (MIC₅₀ and MIC₉₀, 0.5 and 4 μ g/ml, respectively) inhibited 98.9%, 90.3%, and 90.3%, respectively, of the 4,362 *Enterobacteriaceae* isolates tested by using the CLSI breakpoints (Table 2). Among other comparator agents, meropenem (MIC₅₀ and MIC₉₀, 0.03 and 0.06 μ g/ml, respectively; 97.9% susceptible) and tigecycline (MIC₅₀ and MIC₉₀, 0.25 and 1 μ g/ml, respectively; 99.0% susceptible according to U.S. Food and Drug Administration [FDA] breakpoints) were most active against the *Enterobacteriaceae* isolates tested (Table 2).

TABLE 1 Antimicrobial activity of plazomicin tested against 4,825 clinical isolates collected in 70 U.S. hospitals during 2014 to 2015

Organism or group (no. of isolates) ^a	No. (cumulative %) of isolates at MIC (μg/ml) of:												MIC ₅₀ (μg/ml)	MIC ₉₀ (μg/ml)	
	≤0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128			>128
<i>Enterobacteriaceae</i> (4,362)	25 (0.6)	308 (7.6)	971 (29.9)	1,764 (70.3)	822 (89.2)	317 (96.4)	121 (99.2)	13 (99.5)	11 (99.8)	2 (99.8)	3 (99.9)	1 (99.9)	4 (100.0)	0.5	2
<i>Klebsiella pneumoniae</i> (1,506)	18 (1.2)	246 (17.5)	621 (58.8)	580 (97.3)	34 (99.5)	4 (99.8)	1 (99.9)	0 (99.9)	0 (99.9)	0 (99.9)	0 (99.9)	1 (99.9)	1 (100.0)	0.25	0.5
<i>Escherichia coli</i> (1,346)	1 (0.1)	6 (0.5)	75 (6.1)	641 (53.7)	534 (93.4)	81 (99.4)	6 (99.9)	0 (99.9)	0 (99.9)	0 (99.9)	0 (99.9)	0 (99.9)	2 (100.0)	0.5	1
<i>Klebsiella oxytoca</i> (359)	2 (0.6)	17 (5.3)	92 (30.9)	214 (90.5)	27 (98.1)	4 (99.2)	1 (99.4)	0 (99.4)	0 (99.4)	0 (99.4)	1 (99.7)	0 (99.7)	1 (100.0)	0.5	0.5
<i>Enterobacter cloacae</i> species complex (104)	0 (0.0)	14 (13.5)	30 (42.3)	51 (91.3)	8 (99.0)	1 (100.0)								0.5	0.5
<i>Enterobacter aerogenes</i> (120)	2 (1.7)	6 (6.7)	41 (40.8)	53 (85.0)	16 (98.3)	1 (99.2)	1 (100.0)							0.5	1
<i>Serratia marcescens</i> (107)	0 (0.0)	1 (0.9)	5 (5.6)	37 (40.2)	52 (88.8)	9 (97.2)	3 (100.0)							1	2
<i>Citrobacter freundii</i> species complex (159)	0 (0.0)	5 (3.1)	42 (29.6)	91 (86.8)	18 (98.1)	2 (99.4)	1 (100.0)							0.5	1
<i>Citrobacter koseri</i> (145)	2 (1.4)	12 (9.7)	63 (53.1)	58 (93.1)	6 (97.2)	3 (99.3)	1 (100.0)							0.25	0.5
<i>Morganella morganii</i> (118)			0 (0.0)	7 (5.9)	31 (32.2)	38 (64.4)	31 (90.7)	6 (95.8)	2 (97.5)	2 (99.2)	1 (100.0)			2	4
<i>Providencia</i> spp. (158)	0 (0.0)	1 (0.6)	0 (0.6)	18 (12.0)	27 (29.1)	54 (63.3)	44 (91.1)	5 (94.3)	8 (99.4)	0 (99.4)	1 (100.0)			2	4
<i>Proteus mirabilis</i> (124)		0 (0.0)	2 (1.6)	5 (5.6)	23 (24.2)	72 (82.3)	20 (98.4)	2 (100.0)						2	4
<i>Proteus vulgaris</i> group (116)			0 (0.0)	9 (7.8)	46 (47.4)	48 (88.8)	12 (99.1)	0 (99.1)	1 (100.0)					2	4
<i>Pseudomonas aeruginosa</i> (103)	0 (0.0)	1 (1.0)	3 (3.9)	1 (4.9)	3 (7.8)	17 (24.3)	49 (71.8)	17 (88.3)	7 (95.1)	4 (99.0)	0 (99.0)	0 (99.0)	1 (100.0)	4	16
<i>Acinetobacter</i> spp. (95)	1 (1.1)	0 (1.1)	7 (8.4)	14 (23.2)	17 (41.1)	25 (67.4)	7 (74.7)	11 (86.3)	4 (90.5)	4 (94.7)	1 (95.8)	0 (95.8)	4 (100.0)	2	16
Coagulase-negative staphylococci (72)	17 (23.6)	21 (52.8)	26 (88.9)	8 (100.0)										0.12	0.5
<i>Staphylococcus aureus</i> (69)		0 (0.0)	14 (20.3)	51 (94.2)	2 (97.1)	2 (100.0)								0.5	0.5
MRSA (30)		0 (0.0)	9 (30.0)	18 (90.0)	2 (96.7)	1 (100.0)								0.5	0.5
<i>Streptococcus pneumoniae</i> (66)							0 (0.0)	4 (6.1)	32 (54.5)	30 (100.0)				32	64
<i>Enterococcus</i> spp. (58)				0 (0.0)	1 (1.7)	8 (15.5)	7 (27.6)	9 (43.1)	5 (51.7)	8 (65.5)	16 (93.1)	4 (100.0)		16	64

^aMRSA, methicillin-resistant *S. aureus*.

TABLE 2 Activities of plazomicin and comparator agents tested against *Enterobacteriaceae* isolates

Organism group (no. of isolates tested) and antimicrobial agent	MIC ₅₀ (μg/ml)	MIC ₉₀ (μg/ml)	MIC range (μg/ml)	% S using CLSI breakpoints ^a	% S using EUCAST breakpoints ^a
<i>Enterobacteriaceae</i> (4,362)					
Plazomicin	0.5	2	≤0.06–>128		
Amikacin	1	4	≤0.25–>32	98.9	98.0
Gentamicin	0.5	4	≤0.06–>8	90.3	89.2
Tobramycin	0.5	4	≤0.12–>8	90.3	87.1
Ceftazidime	0.12	16	≤0.015–>32	87.9	85.4
Meropenem	0.03	0.06	≤0.015–>32	97.6	97.9
Piperacillin-tazobactam	2	16	≤0.5–>64	92.0	89.2
Colistin	≤0.5	>8	≤0.5–>8		84.0
Tigecycline	0.25	1	≤0.06–4	99.0 ^b	95.7
Levofloxacin	≤0.12	>4	≤0.12–>4	82.9	79.5
CRE (97)					
Plazomicin	0.5	1	≤0.06–>128		
Amikacin	16	32	0.5–>32	64.9	46.4
Gentamicin	2	>8	0.12–>8	56.7	50.5
Tobramycin	>8	>8	0.12–>8	13.4	11.3
Ceftazidime	>32	>32	16–>32	0.0	0.0
Meropenem	16	>32	1–>32	2.1	7.2
Piperacillin-tazobactam	>64	>64	32–>64	0.0	0.0
Colistin	≤0.5	>8	≤0.5–>8		78.1
Tigecycline	0.5	1	0.12–2	100.0 ^b	94.8
Levofloxacin	>4	>4	≤0.12–>4	18.6	11.3
Isolates carrying <i>bla</i> _{KPC} genes (87)					
Plazomicin	0.25	1	≤0.06–>128		
Amikacin	16	32	0.5–>32	63.2	42.5
Gentamicin	4	>8	0.12–>8	55.2	48.3
Tobramycin	>8	>8	0.12–>8	11.5	9.2
Ceftazidime	>32	>32	4–>32	1.1	0.0
Meropenem	16	>32	0.5–>32	3.4	10.3
Piperacillin-tazobactam	>64	>64	64–>64	0.0	0.0
Colistin	≤0.5	>8	≤0.5–>8		78.2
Tigecycline	0.5	1	0.12–2	100.0 ^b	96.6
Levofloxacin	>4	>4	≤0.12–>4	14.9	9.2
Carbapenemase-negative isolates (26)					
Plazomicin	0.5	1	0.12–2		
Amikacin	4	16	0.5–32	92.3	84.6
Gentamicin	1	>8	0.25–>8	69.2	69.2
Tobramycin	2	>8	0.25–>8	57.7	50.0
Ceftazidime	>32	>32	0.25–>32	19.2	15.4
Meropenem	2	32	0.03–32	23.1	53.8
Piperacillin-tazobactam	>64	>64	1–>64	19.2	15.4
Colistin	≤0.5	>8	≤0.5–>8		75.0
Tigecycline	0.5	2	0.06–2	100.0	88.5
Levofloxacin	2	>4	≤0.12–>4	50.0	34.6

^aCriteria reported by the CLSI (14) and EUCAST (15). S, susceptible.

^bBreakpoints from the FDA website (16).

Plazomicin had activity against the majority of *Enterobacteriaceae* isolates resistant to gentamicin and tobramycin (Table 3), inhibiting 96.5% and 95.5% of the gentamicin-resistant isolates according to CLSI and EUCAST breakpoint criteria, respectively, and 96.9% and 96.5% of the tobramycin-resistant isolates according to the same criteria. Only 14 isolates were resistant to amikacin when applying the CLSI criteria, and plazomicin inhibited 9 (64.3%) of these isolates at ≤4 μg/ml. Plazomicin inhibited 90.0% of the 50 amikacin-resistant isolates identified by using the EUCAST breakpoints at ≤4 μg/ml. Five amikacin-resistant isolates had plazomicin MIC values of ≥128 μg/ml and were resistant to gentamicin and tobramycin.

For 103 *P. aeruginosa* isolates, the plazomicin MIC₅₀ and MIC₉₀ values were 4 and 16 μg/ml, respectively. These values were 2-fold higher than those for amikacin and gentamicin (MIC₅₀ and MIC₉₀, 2 and 8 μg/ml, respectively, for both) and 8- to 16-fold

TABLE 3 Activities of plazomicin and comparator aminoglycosides against phenotypes and genotypes of *Enterobacteriaceae* isolates and other Gram-negative species

Organism phenotype or genotype	Source of breakpoint criteria for aminoglycoside resistance (no. of isolates) ^a	% of isolates inhibited by plazomicin at ≤ 4 $\mu\text{g/ml}$	MIC ₅₀ /MIC ₉₀ ($\mu\text{g/ml}$)			
			Plazomicin	Amikacin	Gentamicin	Tobramycin
<i>Enterobacteriaceae</i>	NA (4,362)	99.2	0.5/2	1/4	0.5/4	0.5/4
Amikacin resistant	CLSI (14)	64.3	1/>128	>32/>32	>8/>8	>8/>8
	EUCAST (50)	90.0	0.5/4	32/>32	2/>8	>8/>8
Gentamicin resistant	CLSI (377)	96.6	0.5/2	2/8	>8/>8	>8/>8
	EUCAST (424)	95.5	0.5/2	2/8	>8/>8	>8/>8
Tobramycin resistant	CLSI (292)	96.9	0.5/2	4/32	>8/>8	>8/>8
	EUCAST (423)	96.5	0.5/2	4/32	>8/>8	>8/>8
CRE	NA (97)	99.0	0.5/1	16/32	2/>8	>8/>8
CPE (all carrying <i>bla</i> _{KPC})	NA (87)	98.9	0.25/1	16/32	4/>8	>8/>8
Carbapenemase negative	NA (26)	100.0	0.5/1	4/16	1/>8	2/>8
<i>Pseudomonas aeruginosa</i>	NA (103)	71.8	4/16	2/8	2/8	0.5/1
<i>Acinetobacter baumannii</i>	NA (99)	65.2	2/32	4/>32	1/>8	1/>8

^aNA, not applicable.

higher than those for tobramycin (MIC₅₀ and MIC₉₀, 0.5 and 1 $\mu\text{g/ml}$, respectively) (Tables 1 and 3). Amikacin (97.1% susceptible according to CLSI breakpoints), tobramycin (94.2% susceptible according to CLSI breakpoints), and colistin (98.1% susceptible according to EUCAST breakpoints) (data not shown) were the most active comparators against *P. aeruginosa* isolates.

For 95 *Acinetobacter* species isolates, plazomicin MIC₅₀ and MIC₉₀ values were 4 and 16 $\mu\text{g/ml}$, respectively (Table 1). Amikacin (MIC₅₀ and MIC₉₀, 4 and >32 $\mu\text{g/ml}$, respectively), gentamicin (MIC₅₀ and MIC₉₀, 1 and >8 $\mu\text{g/ml}$, respectively), and tobramycin (MIC₅₀ and MIC₉₀, 1 and >8 $\mu\text{g/ml}$, respectively) (Table 3) inhibited 83.0%, 69.5%, and 77.9% of the isolates, respectively, according to CLSI breakpoint criteria. Among other comparators, only colistin (94.7% susceptible using CLSI or EUCAST criteria), ampicillin-sulbactam (72.3% using CLSI criteria), and imipenem (70.5% using both criteria) inhibited >70.0% of the isolates (data not shown).

All 72 coagulase-negative staphylococci (plazomicin MIC₅₀ and MIC₉₀, 0.12 and 0.5 $\mu\text{g/ml}$, respectively) were inhibited by plazomicin at ≤ 0.5 $\mu\text{g/ml}$, and 69 *S. aureus* (plazomicin MIC₅₀ and MIC₉₀, 0.5 and 0.5 $\mu\text{g/ml}$, respectively) (Table 1) isolates tested were inhibited by plazomicin at ≤ 2 $\mu\text{g/ml}$, including methicillin-resistant isolates (30 isolates tested) (Table 1). Gentamicin inhibited 72.2% and 97.1% of the respective coagulase-negative staphylococcus and *S. aureus* isolates tested at the CLSI breakpoints (data not shown).

Plazomicin had limited antimicrobial activity against *Streptococcus pneumoniae* ($n = 66$; MIC₅₀ and MIC₉₀, 32 and 64 $\mu\text{g/ml}$, respectively) and *Enterococcus* spp. ($n = 58$; MIC₅₀ and MIC₉₀, 16 and 64 $\mu\text{g/ml}$, respectively) (Table 1). As expected, other aminoglycosides also had activities similar to those of plazomicin against these organisms (data not shown).

Activity of plazomicin against carbapenem-resistant and carbapenemase-producing *Enterobacteriaceae*. A total of 97 (2.2% of *Enterobacteriaceae*) CRE isolates were identified in this study. Plazomicin (MIC₅₀ and MIC₉₀, 0.5 and 1 $\mu\text{g/ml}$, respectively) inhibited 99.0% of these isolates at an MIC of ≤ 2 or ≤ 4 $\mu\text{g/ml}$ (Table 2). CRE isolates were highly resistant to comparator agents, but nearly all of them were susceptible to tigecycline (100.0% susceptible according to U.S. FDA breakpoints) (Table 2). Amikacin (MIC₅₀ and MIC₉₀, 16 and 32 $\mu\text{g/ml}$, respectively), gentamicin (MIC₅₀ and MIC₉₀, 2 and >8 $\mu\text{g/ml}$, respectively), and tobramycin (MIC₅₀ and MIC₉₀, >8 and >8 $\mu\text{g/ml}$, respectively) inhibited only 64.9%, 56.7%, and 13.4% of the isolates, respectively, at current CLSI breakpoints (Table 2).

Among 113 isolates displaying imipenem and/or meropenem MIC values of ≥ 2 $\mu\text{g/ml}$, carbapenemases were detected in 87 isolates, including 79 *K. pneumoniae*, 4 *K.*

oxytoca, 2 *C. freundii*, 1 *E. cloacae*, and 1 *S. marcescens* isolates. All isolates carried a *bla*_{KPC} variant: 56 carried *bla*_{KPC-3}, 29 carried *bla*_{KPC-2}, 1 carried *bla*_{KPC-4}, and 1 carried *bla*_{KPC-17}. These isolates were detected in all U.S. census divisions but were observed mainly in the Middle Atlantic division (52 isolates; 59.8% of the carbapenemase-producing *Enterobacteriaceae* [CPE]).

Plazomicin (MIC₅₀ and MIC₉₀, 0.25 and 1 μg/ml, respectively) inhibited 86 of the 87 (98.9%) isolates carrying *bla*_{KPC} at ≤2 or ≤4 μg/ml (Tables 2 and 3). One isolate exhibited a plazomicin MIC at >128 μg/ml, was resistant to all aminoglycosides, and carried the 16S rRNA methyltransferase gene *rmtF1*. Amikacin (MIC₅₀ and MIC₉₀, 16 and 32 μg/ml, respectively), gentamicin (MIC₅₀ and MIC₉₀, 4 and >8 μg/ml, respectively), and tobramycin (MIC₅₀ and MIC₉₀, >8 and >8 μg/ml, respectively) inhibited 63.2 and 42.5%, 55.2 and 48.3%, and 11.5 and 9.2% of the respective CPE isolates according to current CLSI/EUCAST breakpoint criteria.

Carbapenemase-negative isolates included 16 *K. pneumoniae* isolates, 4 *S. marcescens* isolates, and 3 isolates of other species. Plazomicin demonstrated comparable activities against the carbapenemase-negative (MIC₅₀ and MIC₉₀, 0.5 and 1 μg/ml, respectively) and CPE (MIC₅₀ and MIC₉₀, 0.25 and 1 μg/ml, respectively) isolates, and the highest plazomicin MIC value observed was at 2 μg/ml. In contrast, the aminoglycoside comparators were more potent against the 26 carbapenemase-negative isolates than against the CPE isolates. Amikacin (MIC₅₀ and MIC₉₀, 4 and 16 μg/ml, respectively), gentamicin (MIC₅₀ and MIC₉₀, 1 and >8 μg/ml, respectively), and tobramycin (MIC₅₀ and MIC₉₀, 2 and >8 μg/ml, respectively) inhibited 92.3%, 69.2%, and 57.7% of the carbapenemase-negative isolates, respectively, when applying the CLSI breakpoints (Table 2).

DISCUSSION

Patients with prolonged hospitalization, including those in intensive care or long-term-care facilities, immunocompromised patients, and others with malignant conditions, often develop infections, and many of the infections are caused by MDR organisms (1). These organisms include members of the *Enterobacteriaceae* family, including CRE, and pandrug- and extensively drug-resistant *P. aeruginosa*, *A. baumannii*, and Gram-positive species, including *E. faecium* and *S. aureus*. The urgent need for monitoring initiatives and new potential therapeutic options for these organisms has been recognized by the medical and scientific communities, and although various new antimicrobial agents for Gram-positive infections have been approved, the number of non-β-lactam candidates for treating Gram-negative infections in late-stage development is still limited (2–5).

In this study, plazomicin displayed activity against CRE and CPE isolates detected in U.S. hospitals. The majority of the CRE isolates (and all CPE isolates) carried *bla*_{KPC}, and only 1 of these isolates had a plazomicin MIC value of >4 μg/ml. CRE isolates displayed elevated rates of resistance to all β-lactams and comparator agents, including gentamicin and amikacin, which inhibited 63.2% or fewer of the *bla*_{KPC}-carrying isolates at current CLSI or EUCAST breakpoints. Furthermore, plazomicin displayed activity against most isolates resistant to gentamicin and tobramycin according to CLSI or EUCAST breakpoints and inhibited >63% of the amikacin-resistant isolates.

Combination therapy is often used to treat infections caused by CRE, and this might include an aminoglycoside. The *in vitro* results presented here suggest that there is a potential role for this new agent in the antimicrobial armamentarium against difficult-to-treat MDR organisms. These data are supported by the results of 2 recent phase 3 clinical trials that evaluated plazomicin in complicated urinary tract infections and in serious infections due to CRE (i.e., bloodstream infections, hospital-acquired and ventilator-associated bacterial pneumonia, and complicated urinary tract infections) (ClinicalTrials.gov registration numbers NCT02486627 [<https://clinicaltrials.gov/ct2/show/NCT02486627>] and NCT01970371 [<https://clinicaltrials.gov/ct2/show/NCT01970371>]).

Plazomicin demonstrated activity against *Enterobacteriaceae*, *Staphylococcus* spp. regardless of methicillin resistance, and some *P. aeruginosa* and *Acinetobacter* species isolates. A tentative breakpoint of 4 $\mu\text{g/ml}$ was applied during the plazomicin development program and thus was also applied here for the analysis of the *Enterobacteriaceae* population, based on pharmacokinetic/pharmacodynamic (PK/PD) data, which was supported by animal efficacy data (12). By applying this tentative breakpoint, the *in vitro* activity of plazomicin was similar to or greater than those of other aminoglycosides against important organism groups, which include multidrug-resistant isolates, that can pose a challenge for current antimicrobial chemotherapy options.

MATERIALS AND METHODS

Bacterial isolates. A total of 4,825 clinical isolates, including 4,362 *Enterobacteriaceae*, 265 Gram-positive cocci, 103 *P. aeruginosa* isolates, and 95 *Acinetobacter* spp., collected during 2014 and 2015 in 70 hospitals located in 61 U.S. cities were evaluated as part of the ALERT (Antimicrobial Longitudinal Evaluation and Resistance Trends) program. This surveillance program collects key pathogens in targeted numbers (1 per patient episode) deemed to cause urinary tract infections (1,414 isolates), bloodstream infections (1,178), pneumonia in hospitalized patients (1,125), skin and skin structure infections (566), and intra-abdominal infections (441). Other infection sources (101 isolates) were also accepted for uncommon species. Species identification was confirmed, when necessary, by matrix-assisted laser desorption ionization–time of flight mass spectrometry using the Bruker Daltonics MALDI Biotyper (Bruker Daltonics, Billerica, MA, USA), according to the manufacturer's instructions.

Antimicrobial susceptibility testing. All isolates were tested for susceptibility to plazomicin and comparator agents using the reference broth microdilution method described by the CLSI (13). Categorical interpretations for all comparator agents were found in CLSI criteria in document M100 (14), EUCAST breakpoint tables (15), and/or the FDA website (16). Quality control was performed by using *E. coli* ATCC 25922, *S. aureus* ATCC 29213, *P. aeruginosa* ATCC 27853, *Enterococcus faecalis* ATCC 29212, and *S. pneumoniae* ATCC 49619. All quality control MIC results were within acceptable ranges as reported in CLSI documents.

Definitions. CRE was defined as any isolate exhibiting an imipenem, meropenem, or doripenem MIC value of $>2 \mu\text{g/ml}$. *Proteus mirabilis* and indole-positive *Proteaeae* were selected by using meropenem and doripenem only due to the intrinsically elevated imipenem MIC values.

Characterization of carbapenemases. Isolates nonsusceptible to imipenem or meropenem were screened by PCR followed by DNA sequencing of *bla*_{KPC}, *bla*_{IMP}, *bla*_{VIM}, *bla*_{NDM}, *bla*_{OXA-48}, *bla*_{GES} (*bla*_{GES-2}, *bla*_{GES-4}, *bla*_{GES-5}, *bla*_{GES-6}, and *bla*_{GES-8}), *bla*_{NMC-A}, *bla*_{SME}, and *bla*_{IMI} (17). Isolates yielding negative results for these genes were tested for less common carbapenemases, including genes encoding FRI-1, BKC-1, GIM-1/-2, SIM-1, SPM-1, KHM-1, AIM-1, BIC-1, and DIM-1 (18).

Amplicons generated were sequenced on both strands, and the nucleotide sequences obtained were analyzed by using the Lasergene software package (DNASar, Madison, WI, USA) and compared to available sequences via an NCBI BLAST search (<http://www.ncbi.nlm.nih.gov/blast/>).

ACKNOWLEDGMENTS

We thank the JMI staff for their technical expertise in all stages of this study and manuscript preparation.

This study was performed by JMI Laboratories and supported by Achaogen, which included funding for services related to preparing the manuscript.

JMI Laboratories was contracted to perform services in 2017 for Achaogen; Allegra Therapeutics; Allergan; Amlyx Pharmaceuticals; Antabio; API; Astellas Pharma; Astra-Zeneca; Athelas; Basilea Pharmaceutica; Bayer AG; BD; Becton, Dickinson and Co.; Boston Pharmaceuticals; CEM-102 Pharma; Cempra; Cidara Therapeutics, Inc.; CorMedix; CSA Biotech; Cutanea Life Sciences, Inc.; Entasis Therapeutics, Inc.; Geom Therapeutics, Inc.; GSK; Iterum Pharma; Medpace; Melinta Therapeutics, Inc.; Merck & Co., Inc.; MicuRx Pharmaceuticals, Inc.; N8 Medical, Inc.; Nabriva Therapeutics, Inc.; NAEJA-RGM; Novartis; Paratek Pharmaceuticals, Inc.; Pfizer; Polyphor; Ra Pharma; Rempex; Riptide Bioscience, Inc.; Roche; Scynexis; Shionogi; Sinsa Labs, Inc.; Skyline Antiinfectives; Sonoran Biosciences; Spero Therapeutics; Symbiotica; Synlogic; Synthes Biomaterials; TenNor Therapeutics; Tetrphase; The Medicines Company; Theravance Biopharma; VenatoRx Pharmaceuticals, Inc.; Wockhardt; Yukon Pharma; Zai Laboratory; and Zavante Therapeutics, Inc. There are no speakers' bureaus or stock options to declare. A.W.S. and K.M.K. are employees of Achaogen and contributed with the design of the study and review of the manuscript but not with analyzing or interpreting the results.

REFERENCES

1. Pogue JM, Kaye KS, Cohen DA, Marchaim D. 2015. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. *Clin Microbiol Infect* 21:302–312. <https://doi.org/10.1016/j.cmi.2014.12.025>.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis* 48:1–12. <https://doi.org/10.1086/595011>.
3. Bassetti M, Merelli M, Temperoni C, Astilean A. 2013. New antibiotics for bad bugs: where are we? *Ann Clin Microbiol Antimicrob* 12:22. <https://doi.org/10.1186/1476-0711-12-22>.
4. Savage RD, Fowler RA, Rishu AH, Bagshaw SM, Cook D, Dodek P, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall J, Martin CM, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Daneman N. 2016. The effect of inadequate initial empiric antimicrobial treatment on mortality in critically ill patients with bloodstream infections: a multi-centre retrospective cohort study. *PLoS One* 11:e0154944. <https://doi.org/10.1371/journal.pone.0154944>.
5. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. 2003. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. *Clin Microbiol Infect* 9:412–418. <https://doi.org/10.1046/j.1469-0691.2003.00656.x>.
6. Ramirez MS, Tolmasky ME. 2010. Aminoglycoside modifying enzymes. *Drug Resist Updat* 13:151–171. <https://doi.org/10.1016/j.drug.2010.08.003>.
7. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. 1999. Aminoglycosides: activity and resistance. *Antimicrob Agents Chemother* 43:727–737.
8. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. *Antimicrob Agents Chemother* 54:4636–4642. <https://doi.org/10.1128/AAC.00572-10>.
9. Cox G, Ejim L, Stogios PJ, Koteva K, Borderleau E, Evdokimova E, Sieron AO, Serio AW, Krause KM, Wright GD. 2018. Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. *ACS Infect Dis* 4:980–987. <https://doi.org/10.1021/acinfecdis.8b00001>.
10. Karaiskos I, Souli M, Giamarellou H. 2015. Plazomicin: an investigational therapy for the treatment of urinary tract infections. *Expert Opin Invest Drugs* 24:1501–1511. <https://doi.org/10.1517/13543784.2015.1095180>.
11. Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2012. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. *Expert Rev Anti Infect Ther* 10:459–473. <https://doi.org/10.1586/eri.12.25>.
12. Abdelraouf K, Kim A, Krause KM, Nicolau DP. 2017. Assessment of the *in vivo* of plazomicin alone or in combination with meropenem or tigecycline against *Enterobacteriaceae* isolates exhibiting various resistance mechanisms in an immunocompetent murine septicemia model, poster 1506. *Abstr IDWeek 2017*, 4 to 8 October 2017, San Diego, CA.
13. CLSI. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI, Wayne, PA.
14. CLSI. 2017. M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. CLSI, Wayne, PA.
15. EUCAST. 2017. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0, January 2017. http://www.eucast.org/clinical_breakpoints/. Accessed January 2017.
16. U.S. Food and Drug Administration. 2017. Tigecycline–injection products. FDA-identified interpretive criteria. U.S. Food and Drug Administration, Silver Spring, MD. <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm587585.htm>. Accessed June 2018.
17. Castanheira M, Mendes RE, Woosley LN, Jones RN. 2011. Trends in carbapenemase-producing *Escherichia coli* and *Klebsiella* spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007–09). *J Antimicrob Chemother* 66:1409–1411. <https://doi.org/10.1093/jac/dkr081>.
18. Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis* 70:119–123. <https://doi.org/10.1016/j.diagmicrobio.2010.12.002>.